靶向急性髓系白血病对嘌呤从头合成途径的特异性依赖
本研究通过全基因组CRISPR/Cas9筛选及体内二次筛选,鉴定出嘌呤从头合成酶PAICS为急性髓系白血病(AML)的潜在治疗靶点。抑制PAICS可抑制DNA合成、促进凋亡,在AML细胞及PDX模型中显示抗白血病效应,并鉴定了介导耐药或合成致死的基因。
要点
- PAICS是AML的潜在治疗靶点
- PAICS抑制剂抑制增殖并诱导凋亡
- 鉴定耐药及合成致死相关基因
核心结论
- PAICS是AML新的治疗靶点
- 嘌呤从头合成途径及其下游效应分子对AML细胞存活至关重要
研究设计与样本
- 在AML细胞系中进行全基因组CRISPR/Cas9筛选,随后进行体内二次筛选
- 使用shRNA-PAICS及PAICS抑制剂处理人AML细胞
- 在AML PDX模型中评估PAICS抑制剂的抗白血病效果
- 在抑制剂存在下对AML细胞进行CRISPR/Cas9筛选以鉴定耐药或合成致死基因
主要发现
- 表达shRNA-PAICS的AML细胞表现出增殖劣势
- PAICS抑制剂通过抑制DNA合成和促进凋亡抑制人AML细胞增殖
- PAICS抑制剂在AML PDX模型中具有抗白血病效应
- CRISPR/Cas9筛选鉴定了介导对PAICS抑制耐药或合成致死的基因
临床怎么用
- PAICS可作为AML治疗的潜在靶点进行进一步开发
- 嘌呤从头合成途径及其下游效应分子可能作为联合治疗策略的依据
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML) is a devastating disease, and clinical outcomes are still far from satisfactory. Here, to identify novel targets for AML therapy, we performed a genome-wide CRISPR/Cas9 screen using AML cell lines, followed by a second screen in vivo. We show that PAICS, an enzyme involved in de novo purine biosynthesis, is a potential target for AML therapy. AML cells expressing shRNA-PAICS exhibited a proliferative disadvantage, indicating a toxic effect of shRNA-PAICS. Treatment of human AML cells with a PAICS inhibitor suppressed their proliferation by inhibiting DNA synthesis and promoting apoptosis and had anti-leukemic effects in AML PDX models. Furthermore, CRISPR/Cas9 screens using AML cells in the presence of the inhibitor revealed genes mediating resistance or synthetic lethal to PAICS inhibition. Our findings identify PAICS as a novel therapeutic target for AML and further define components of de novo purine synthesis pathway and its downstream effectors essential for AML cell survival.
引用
- Yamauchi T, Miyawaki K, Semba Y, et al. Targeting leukemia-specific dependence on the de novo purine synthesis pathway. Leukemia. 2021. PMID: 34344987. doi:10.1038/s41375-021-01369-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。